In terms of clinical outcome, a study of 443 breast cancer patients demonstrated that there was no association between native ezrin staining intensity and clinical outcome, but was significantly associated with recurrence when expression was normalised against matched normal tissue expression for each tumour core9; there have been further studies that have shown no significant association between patient survival and ezrin expression in unselected patient cohorts in 120 patients, and 347 patients.5, 10. The gene discussed is EZR; the disease is breast carcinoma.